Clin-nov Medical Executive and Leadership Team

Rui Yang, the Chief Executive Officer at Clin-nov Medical, directs the overarching strategy and operational execution for the contract research organization. Yang guides the company's mission to advance new treatments for patients globally, ensuring scientific rigor remains central to all drug research and development solutions offered to the pharmaceutical industry. This leadership role involves fostering innovation and maintaining the highest standards of service delivery. Yang oversees the integration of cutting-edge technologies that enable the acceleration of therapeutic advancements. The Chief Executive Officer's focus is on strategic partnerships and long-term growth, solidifying Clin-nov Medical's position as a leader in R&D support. Rui Yang drives the company's commitment to scientific excellence and patient-centric outcomes.

Da Zhang, the Chief Financial Officer at Clin-nov Medical, manages the financial health and strategic fiscal planning for the contract research organization. Zhang oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring the company's ability to deliver comprehensive drug research and development solutions. This leadership position is critical for maintaining financial stability and supporting the company's growth initiatives aimed at advancing new treatments for patients globally. The Chief Financial Officer's purview includes managing investor relations and optimizing financial performance to sustain scientific innovation. Da Zhang ensures that financial strategies align with the company's mission, providing the necessary resources to drive R&D advancements and support pharmaceutical industry partners. Zhang's fiscal oversight is integral to Clin-nov Medical's operational success and its commitment to patient well-being.

Ruiling Peng, the Chief Technology Officer at Clin-nov Medical, architects the technological infrastructure and innovation pipeline that underpins the company's drug research and development solutions. Peng spearheads the adoption and development of advanced technologies, ensuring Clin-nov Medical remains at the forefront of scientific discovery for pharmaceutical partners. This involves managing the integration of novel platforms that enhance the efficiency and effectiveness of R&D processes. The Chief Technology Officer's responsibilities extend to ensuring the scalability and security of all technological systems, supporting the company's mission to accelerate new treatments for patients worldwide. Peng drives technological strategy, aligning innovation with the core business objectives of advancing patient care through scientific breakthroughs. Ruiling Peng ensures the technological capabilities directly support client success in bringing therapies to market.

Xinhui Hu, the Chief Technology Officer, Cbo at Clin-nov Medical, drives the strategic integration of technology with business development initiatives, focusing on expanding the reach and impact of the company's drug research and development solutions. Hu oversees the technological roadmap that supports new market penetration and client acquisition, ensuring that Clin-nov Medical's innovative platforms are leveraged to their fullest potential. This dual role emphasizes translating technological advancements into tangible business opportunities, thereby accelerating the development of new treatments for patients worldwide. The Chief Technology Officer, Cbo's responsibilities include identifying emerging technological trends and forging strategic partnerships that enhance the company's service offerings. Xinhui Hu ensures that technological innovation directly fuels business growth and strengthens Clin-nov Medical's position in the pharmaceutical R&D landscape. Hu's leadership bridges the gap between cutting-edge science and market expansion.